Holen Sie sich die Stockscreener-App
10.46
0.19%
0.02
Handel nachbörslich:
11.03
0.57
+5.45%
Schlusskurs vom Vortag:
$10.44
Offen:
$10.42
24-Stunden-Volumen:
128.23K
Relative Volume:
5.91
Marktkapitalisierung:
$740.34M
Einnahmen:
$370.44M
Nettoeinkommen (Verlust:
$12.19M
KGV:
60.71
EPS:
0.1723
Netto-Cashflow:
$50.74M
1W Leistung:
-0.85%
1M Leistung:
-11.13%
6M Leistung:
-35.55%
1J Leistung:
-29.32%
1-Tages-Spanne:
$10.25
$11.15
1-Wochen-Bereich:
$10.25
$11.50
52-Wochen-Spanne:
$9.62
$21.34
Pharming Group Nv Adr Stock (PHAR) Company Profile
Firmenname
Pharming Group Nv Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare PHAR vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHAR
Pharming Group Nv Adr
|
10.46 | 740.34M | 370.44M | 12.19M | 50.74M | 0.1723 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharming Group Nv Adr Stock (PHAR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-12-09 | Eingeleitet | Jefferies | Buy |
Pharming Group Nv Adr Aktie (PHAR) Neueste Nachrichten
Pharming Group says FDA accepts lower-dose Joenja sNDA for review - Mugglehead Investment Magazine
FDA Grants Priority Review to Pharming's Joenja for Younger, Lower-Weight APDS Patients - Kalkine Media
Canaccord reiterates Pharming stock rating on positive trial data - Investing.com
Pharming Group N.V. (PHAR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Pharming Group N.V. stock gains on MAC Alpha Capital’s new USD 29.84 million stake - AD HOC NEWS
Pharming Group (NASDAQ: PHAR) Secures FDA Nod for Pediatric Use of Joenja in APDS Treatment - Kalkine Media
Zai Lab LimitedADR Peer Comparison – Compare with Others - Value Research
Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research
Pharming Group N.V. ADS each representing 10 (PHAR) Peer Comparison – Compare with Others - Value Research
XORTX Therapeutics Inc. (XRTX) Peer Comparison – Compare with Others - Value Research
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 93.0% in July - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by Brokerages - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Gap DownShould You Sell? - MarketBeat
Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pharming Grou - The National Law Review
Pharming Group (PHAR) Securities Investigation NoticeLevi & Korsinsky - Sahm
Pharming Group (NASDAQ:PHAR) Shares Gap UpTime to Buy? - MarketBeat
Q3 EPS Estimates for Pharming Group Lowered by HC Wainwright - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Gap Down Following Weak Earnings - MarketBeat
Pharming Q2 2026 slides: Joenja growth offsets RUCONEST pressure - Investing.com
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update - MarketBeat
Pharming Group NV Sponsored ADR Revenue Breakdown – DUS:PHG - TradingView
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by Analysts - MarketBeat
Pharming Q1 2026 slides: Joenja growth offset by RUCONEST decline - Investing.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Pharming Group N.V - The National Law Review
A2QLQY Forecast — Price Target — Prediction for 2027 - TradingView
Pharming Group NV Sponsored ADR Actuals & Estimates (NASDAQ:PHAR) - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Pharming earnings in focus: Can rare disease growth offset Q1 dip? - Investing.com
Form 6K Pharming Group NV For: 28 May By Investing.com - Investing.com South Africa
PHARPharming Group NV ADR Stock Price and Quote - Finviz
Pharming Group gears up to report Q4 earnings: What's in the cards? - MSN
PHARM.AS Stock Price, Quote & Chart | PHARMING GROUP NV (AMS:PHARM) - ChartMill
Earnings call transcript: Pharming Group Q1 2026 revenue declines amid RUCONEST challenges By Investing.com - Investing.com South Africa
Earnings call transcript: Pharming Group Q1 2026 revenue declines amid RUCONEST challenges - Investing.com India
Pharming Group Q1 Earnings Call Highlights - Barchart.com
Earnings call transcript: Pharming Group Q1 2026 sees stock drop amid revenue decline - Investing.com
Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026 - GlobeNewswire Inc.
Pharming earnings in focus: Can rare disease growth offset Q1 dip? By Investing.com - Investing.com South Africa
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Finanzdaten der Pharming Group Nv Adr-Aktie (PHAR)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):